MedTrace Logo

Migraine Survey in Gulf Region

NCT06237062 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2025-11-20

No results posted yet for this study

Summary

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

Conditions

Interventions

OTHER

erenumab

This was an observational study, there was no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients were directed through a link to the full survey.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-05
Primary Completion
2024-11-18
Completion
2024-11-18

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06237062 on ClinicalTrials.gov